BioCentury | Sep 10, 2020
Finance

Casma to advance muscle dystrophy candidate into the clinic with $50M series B

...November, Merck & Co. Inc. (NYSE:MRK) acquired Calporta Therapeutics Inc. and...
...Golovin Casma Therapeutics Inc. The Column Group Merck & Co. Inc. Calporta Therapeutics Inc. Third...
BioCentury | Nov 13, 2019
Company News

Merck acquiring Avalon lysosomal disorder play Calporta

...channel in autophagy, to treat lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Calporta Therapeutics Inc....
BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...patients next year in a trial. Based on research conducted at the University of Michigan, Calporta Therapeutics Inc....
BioCentury | Aug 17, 2017
Finance

Built to purpose

...and GSK -- entered new territory as the first to announce programs for unexploited targets. Calporta Therapeutics Inc....
...Jolla, Calif. Bay City Capital, San Francisco, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Calporta Therapeutics Inc....
BioCentury | Jun 22, 2015
Company News

Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, GlaxoSmithKline cancer, cardiology, endocrine/metabolic news

...29, 2014). Adrenergics Inc. , San Diego, Calif. CadheRx Therapeutics Inc. , San Diego, Calif. Calporta Therapeutics Inc....
BioCentury | Jun 22, 2015
Finance

Build-to-buy basket

...the VC. The newest cohort of companies includes Adrenergics Inc. , CadheRx Therapeutics Inc. and Calporta Therapeutics Inc....
BioCentury | Jun 22, 2015
Financial News

Calporta Therapeutics completes venture financing

Calporta Therapeutics Inc. , San Diego, Calif. Business: Endocrine/Metabolic Date completed: 2015-06-15 Type: Venture financing Raised: $3 million Investors: Avalon Ventures; GlaxoSmithKline plc WIR Staff...
BioCentury | Jun 16, 2015
Financial News

Avalon, GSK launch three more biotechs

...is developing antibodies against E-cadherin ( CDH1 ; CD324 ) to treat drug-resistant epithelial cancers. Calporta Therapeutics Inc....
Items per page:
1 - 8 of 8
BioCentury | Sep 10, 2020
Finance

Casma to advance muscle dystrophy candidate into the clinic with $50M series B

...November, Merck & Co. Inc. (NYSE:MRK) acquired Calporta Therapeutics Inc. and...
...Golovin Casma Therapeutics Inc. The Column Group Merck & Co. Inc. Calporta Therapeutics Inc. Third...
BioCentury | Nov 13, 2019
Company News

Merck acquiring Avalon lysosomal disorder play Calporta

...channel in autophagy, to treat lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Calporta Therapeutics Inc....
BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...patients next year in a trial. Based on research conducted at the University of Michigan, Calporta Therapeutics Inc....
BioCentury | Aug 17, 2017
Finance

Built to purpose

...and GSK -- entered new territory as the first to announce programs for unexploited targets. Calporta Therapeutics Inc....
...Jolla, Calif. Bay City Capital, San Francisco, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Calporta Therapeutics Inc....
BioCentury | Jun 22, 2015
Company News

Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, GlaxoSmithKline cancer, cardiology, endocrine/metabolic news

...29, 2014). Adrenergics Inc. , San Diego, Calif. CadheRx Therapeutics Inc. , San Diego, Calif. Calporta Therapeutics Inc....
BioCentury | Jun 22, 2015
Finance

Build-to-buy basket

...the VC. The newest cohort of companies includes Adrenergics Inc. , CadheRx Therapeutics Inc. and Calporta Therapeutics Inc....
BioCentury | Jun 22, 2015
Financial News

Calporta Therapeutics completes venture financing

Calporta Therapeutics Inc. , San Diego, Calif. Business: Endocrine/Metabolic Date completed: 2015-06-15 Type: Venture financing Raised: $3 million Investors: Avalon Ventures; GlaxoSmithKline plc WIR Staff...
BioCentury | Jun 16, 2015
Financial News

Avalon, GSK launch three more biotechs

...is developing antibodies against E-cadherin ( CDH1 ; CD324 ) to treat drug-resistant epithelial cancers. Calporta Therapeutics Inc....
Items per page:
1 - 8 of 8